NCT03917966招募中2 期
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2020年4月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Major pathological response（MPR）
研究概览
简要总结
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma
详细描述
In China, the incidence of esophageal cancer has declined in recent years, but the mortality rate has been ranked fourth. Morbidity and mortality were ranked sixth and fourth in all malignancies, respectively. Therefore, esophageal cancer has always been a major malignant tumor that threatens the health of our residents. Investigator designed a single-arm, open-label, phase II trial of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma. The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-80 years old, both men and women;
- •Histology confirmed as esophageal squamous cell carcinoma;
- •Resectable stage Ⅱ/Ⅲ/Ⅳa（cT2-4aN0-3M0）;
- •ECOG: 0~1;
- •Expected survival period≥12 weeks;
- •The main organs function normally, that is, the following criteria are met:(1)Blood routine examination:a.HB≥90g/L; b.ANC≥1.5×109 / L; c.PLT≥80×109 / L (2)Biochemical examination:a.ALB≥30g / L; b.ALT and AST≤2.5ULN; if there is liver metastasis, ALT and AST ≤ 5ULN; c.TBIL ≤1.5ULN;d.plasma Cr≤1.5ULN or creatinine clearance (CCr) ≥ 60ml / min;
- •Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ normal low limit (50%);
- •Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; negative serum or urine pregnancy test within 7 days prior to study enrollment And must be non-lactating patients; males should agree to patients who must use contraception during the study period and within 6 months after the end of the study period;
- •Subjects voluntarily joined the study, signed informed consent, and were well-adhered to follow-up;
- •Can swallow tablets normally.
排除标准
- •Does not meet the above inclusion criteria;
- •Those who are allergic to or sensitive to Docetaxel and nedaplatin;
- •The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis,Hyperthyroidism; patients with vitiligo; Asthma has been completely relieved in childhood, and patients who do not need any intervention after adulthood can be included; asthma patients who require bronchodilators for medical intervention cannot be included);
- •The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppressive purposes (dose > 10 mg/day of prednisone or other therapeutic hormones) and continues to be used for 2 weeks prior to enrollment;
- •Patients with any severe and/or uncontrolled diseases:Patients with unsatisfactory blood pressure control (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100 mmHg); myocardial ischemia or myocardial infarction with grade I or above, arrhythmia (including QT interval ≥480ms) and grade I cardiac insufficiency;
- •Active or uncontrolled serious infections;
- •Liver diseases such as decompensated liver disease, active hepatitis B (HBV-DNA ≥ 104 copies/ml or 2000 IU/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method);
- •Urine routine indicates that urine protein ≥ ++, and confirmed 24-hour urine protein quantitation > 1.0g;
- •Pregnant or lactating women;
- •Patients with other malignancies within 5 years (except for basal cell carcinoma and cervical carcinoma in situ) that have been cured;
- •Patients with a history of psychotropic substance abuse who are unable to quit or have a mental disorder;
- •Patients who have participated in other drug clinical trials within four weeks;
- •At the discretion of the investigator, there are patients with serious concomitant disease that compromises patient safety or affects the patient's completion of the study;
- •The investigator believes that it is not suitable for inclusion;
- •Patients with esophageal squamous cell carcinoma whose primary focus is active bleeding;
- •With active ulcer, unhealed wound or fracture;
- •Suffer from hypertension and cannot be well controlled by antihypertensive drugs (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg);
- •Abnormal coagulation function (INR > 2.0 or prothrombin time (PT) > 16S), bleeding tendency or undergoing thrombolytic or anticoagulant therapy (preventive use of low-dose aspirin and low molecular weight heparin is allowed);
- •Patients with clinically significant bleeding symptoms or definite bleeding tendency within the first three months of randomization, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or vasculitis, can be reexamined if the stool occult blood is positive in the baseline period. If it is still positive after reexamination, endoscopic examination is required (except those who have accepted endoscopic examination within three months before enrollment and excluded such cases);
- •Arteriovenous thrombosis events occurred within the first 6 months of randomization, such as cerebrovascular accidents (including transient ischemic attack, intracerebral hemorrhage and cerebral infarction), deep venous thrombosis and pulmonary embolism;
- •Known hereditary or acquired bleeding and thrombotic tendency (such as hemophilia, coagulation dysfunction, thrombocytopenia, etc.);
- •Routine urine examination showed that urinary protein was ≥ + + and it was confirmed that the amount of urinary protein in 24 hours was > 1.0 g;
- •Patients with supraclavicular lymph node metastasis; Poor nutritional status, BMI < 18.5 kg / m2; If it is corrected before randomization after symptomatic nutritional support, it can continue to be considered after evaluation by the main investigator
研究组 & 干预措施
SHR-1210+Docetaxel+nedaplatin
Experimental
SHR-1210+Docetaxel+nedaplatin
干预措施: SHR-1210+docetaxel+nedaplatin (Drug)
SHR-1210+Apatinib
Experimental
SHR-1210+Apatinib
干预措施: SHR-1210+Apatinib (Drug)
结局指标
主要结局
Major pathological response（MPR）
时间窗: At time of surgery
defined as ≤ 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory.
次要结局
- Overall Survival (OS)(up to 2 year)
- Disease-Free Survival (DFS)(up to 2 year)
- Pathological Complete Response (pCR)(At time of surgery)
- Lymph node derating rate(At time of surgery)
- R0 resection rate(At time of surgery)
研究者
Feng Wang
Director
The First Affiliated Hospital of Zhengzhou University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)Carcinoma, Non-Small-Cell LungNCT03083041Jiangsu HengRui Medicine Co., Ltd.210
Unknown
2 期
A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaResectable Esophageal Squamous Cell CarcinomaNCT04533490The First Affiliated Hospital of Zhengzhou University42
终止
3 期
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.Non-squamous Non-small-cell Lung CancerNCT04619433Jiangsu HengRui Medicine Co., Ltd.48
已完成
1 期
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCTriple Negative Breast CancerNCT03945604Jiangsu HengRui Medicine Co., Ltd.32
已完成
2 期
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerGastroEsophageal CancerGastric CancerNCT03472365Jiangsu HengRui Medicine Co., Ltd.67